AbbVie Inc. (NYSE:ABBV) Shares Sold by Schnieders Capital Management LLC

Schnieders Capital Management LLC lessened its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 36.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,831 shares of the company's stock after selling 9,795 shares during the quarter. Schnieders Capital Management LLC's holdings in AbbVie were worth $2,991,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. RPg Family Wealth Advisory LLC purchased a new stake in shares of AbbVie in the 3rd quarter valued at $28,000. Fiduciary Advisors Inc. acquired a new position in AbbVie in the 4th quarter valued at about $29,000. Bradley & Co. Private Wealth Management LLC purchased a new stake in AbbVie during the fourth quarter worth about $31,000. Retirement Wealth Solutions LLC acquired a new stake in shares of AbbVie during the fourth quarter worth about $35,000. Finally, Mizuho Securities Co. Ltd. boosted its stake in shares of AbbVie by 100.0% in the third quarter. Mizuho Securities Co. Ltd. now owns 200 shares of the company's stock valued at $39,000 after purchasing an additional 100 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

Shares of ABBV stock traded up $2.05 during mid-day trading on Thursday, hitting $205.06. 5,692,933 shares of the stock were exchanged, compared to its average volume of 5,871,798. The stock has a market capitalization of $362.00 billion, a price-to-earnings ratio of 85.44, a P/E/G ratio of 1.62 and a beta of 0.58. AbbVie Inc. has a 12-month low of $153.58 and a 12-month high of $207.32. The stock's fifty day simple moving average is $183.75 and its two-hundred day simple moving average is $186.85. The company has a debt-to-equity ratio of 17.94, a quick ratio of 0.55 and a current ratio of 0.66.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same quarter in the previous year, the business earned $2.79 EPS. On average, analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a $1.64 dividend. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.20%. AbbVie's payout ratio is 273.33%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 5,778 shares of the company's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $197.90, for a total transaction of $1,143,466.20. Following the completion of the transaction, the executive vice president now owns 22,381 shares in the company, valued at approximately $4,429,199.90. This represents a 20.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Kevin K. Buckbee sold 1,800 shares of the business's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the transaction, the senior vice president now owns 6,983 shares in the company, valued at approximately $1,202,751.92. This trade represents a 20.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.25% of the company's stock.

Analyst Ratings Changes

ABBV has been the topic of a number of research reports. Daiwa America lowered shares of AbbVie from a "strong-buy" rating to a "hold" rating in a report on Thursday, December 5th. Daiwa Capital Markets cut AbbVie from an "outperform" rating to a "neutral" rating and set a $180.00 price objective on the stock. in a research note on Thursday, December 5th. Leerink Partnrs raised AbbVie from a "hold" rating to a "strong-buy" rating in a research note on Friday, November 22nd. Wolfe Research initiated coverage on AbbVie in a research report on Friday, November 15th. They issued an "outperform" rating and a $205.00 price target on the stock. Finally, Argus upgraded AbbVie from a "hold" rating to a "buy" rating in a research note on Monday, November 4th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $208.35.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.